Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-45838

ABSTRACT: Knock-down of BCL6 expression in human Diffuse Large B-Cell Lymphoma cell lines

PROVIDER: E-GEOD-45838 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-45838-analysis-methods.tsv	Tabular
	E-GEOD-45838-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-45838-configuration.xml	Xml
	E-GEOD-45838-percentile-ranks.tsv	Tabular
	E-GEOD-45838.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 66

Similar Datasets

E-GEOD-51651

Project description:Expression data from control and GAPLINC knock down human gastric cancer cell lines

2025-01-24 | E-GEOD-51651 | ExpressionAtlas

Homo sapiens

Project description:Knock-down of BCL6 expression in human Diffuse Large B-Cell Lymphoma cell lines

| PRJNA196519 | ENA

E-GEOD-5681

Project description:Transcription profiling of human T-cell lymphoblastic leukemia, acute mylelogenous leukemia and Diffuse Large Cell Lymphoma cell lines after treatment with aplidin and/or cytarabine

2025-01-24 | E-GEOD-5681 | ExpressionAtlas

E-GEOD-51704

Project description:Gene expression profiling of KLF5, GATA4 and GATA6 knock down in YCC3/AGS/KATOIII cell lines

2025-01-24 | E-GEOD-51704 | ExpressionAtlas

Frequent mutations of FBXO11 identify BCL6 as a therapeutic target in Burkitt Lymphoma

Project description:BCL6 is a key oncogene in lymphoma pathogenesis. The expression of BCL6 in lymphoid cells can be deregulated by several mechanisms, including chromosomal translocations, somatic mutations in the promoter regulatory regions or reduced proteasome-mediated degradation. FBXO11 was recently identified as a major ubiquitin ligase involved in the degradation of BCL6 and is frequently inactivated in diffuse large B-cell lymphoma (DLBCL). In this work, we found that FBXO11 is frequently mutated in Burkitt lymphoma (BL) but rarely mutated in other BCL6-positive lymphomas, such as follicular lymphoma (FL). All mutations tested impaired FBXO11 mediated BCL6 degradation and FBXO11 knock-out completely stabilized BCL6 levels in human BL cell lines. Conditional deletion of one copy or both copies of FBXO11 in c-Myc-driven B cell lymphoma in mice accelerated lymphomagenesis, genetically confirming that FBXO11 is a haplo-insufficient oncosuppressor in lymphoma. In both FBOX11 WT and deficient BL mouse and human cell lines, blockade of BCL6 via a specific degrader or BCL6 inhibitors, impaired lymphoma growth in vitro and in vivo, an effect further enhanced by co-inhibition of c-Myc activity. Overall these findings not only establish FBXO11 as one of the most frequently mutated genes in BL, but also elucidate its biological functions in lymphomagenesis and thereby identify BCL6 as a specific therapeutic target in BL.

2021-12-31 | GSE159303 | GEO

E-GEOD-59234

Project description:Gene expression data from SOX2 knock-out 2102Ep and NTera-2 human embryonal carcinoma cell lines

2025-01-24 | E-GEOD-59234 | ExpressionAtlas

EZH2 and BCL6 cooperate to assemble CBX8-BCOR Polycomb complex to repress bivalent promoters, mediate germinal center formation and promote lymphomagenesis [RNA-seq]

Project description:EZH2 mediates the humoral immune response and drives lymphomagenesis through de novo formation of bivalent chromatin domains and critical germinal center (GC) B cell promoters. We show that such formation is dependent on the presense of BCL6 and the presence of non-canonical PRC1-BCOR complex. We observe that BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in vitro, in vivo, and in primary human DLBCLs. DLBCL cell lines treated with BCL6 inhibitor 79-6.1085

2016-07-20 | E-GEOD-73109 | biostudies-arrayexpress

E-GEOD-5823

Project description:Transcription profiling by array of human breast and cervical cancer cell lines after RNAi-mediated knock-down of c-MYC

2025-01-24 | E-GEOD-5823 | ExpressionAtlas

E-GEOD-49284

Project description:Expression data from EZH2 inhibitor treated Non-Hodgkins Lymphoma cell lines

2025-01-24 | E-GEOD-49284 | ExpressionAtlas

Relocalizing transcriptional kinases to activate apoptosis_Proteomics Data

Project description:Kinases are critical regulators of cellular function that are commonly implicated in the mechanisms underlying disease. Most drugs that target kinases are molecules that inhibit their catalytic activity, but here we used chemically induced proximity to convert kinase inhibitors into activators of therapeutic genes. We synthesized bivalent molecules that link ligands of the transcription factor B cell lymphoma 6 (BCL6) to inhibitors of cyclin-dependent kinases (CDKs). These molecules relocalized CDK9 to BCL6-bound DNA and directed phosphorylation of RNA polymerase II. The resulting expression of pro-apoptotic, BCL6-target genes caused killing of diffuse large B cell lymphoma cells and specific ablation of the BCL6-regulated germinal center response. Genomics and proteomics corroborated a gain-of-function mechanism in which global kinase activity was not inhibited but rather redirected. Thus, kinase inhibitors can be used to context-specifically activate transcription. This PRIDE entry contains the raw proteomics data and DIA-NN search output.

2024-12-20 | PXD051502 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data